New drug with chemo for advanced pancreatic cancer with KRAS G12D mutation
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug (DN022150) combined with standard chemotherapy (AG) as a first treatment for advanced or metastatic pancreatic cancer that has a specific gene change called KRAS G12D. It may help people who haven't had other treatments for this stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic pancreatic cancer with a KRAS G12D mutation.
- You haven't received any previous drug treatment for this stage of cancer.
- You are between 18 and 75 years old.
- You are in generally good health (able to do daily activities with minimal help).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares an experimental drug called DN022150 to standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It is for those who have already tried other treatments.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.